Online inquiry

IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7127MR)

This product GTTS-WQ7127MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LHCGR gene. The antibody can be applied in Controlled Ovarian Stimulation (COS) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000233.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3973
UniProt ID P22888
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LHCGR, FE 999302(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7127MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2055MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ4178MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ3284MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ15701MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ13724MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ5945MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CL-2C
GTTS-WQ15410MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ14959MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SHR-1210
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW